HOOKIPA Pharma Inc. (HOOK)
| Bid | 0.73 |
| Market Cap | 9.38M |
| Revenue (ttm) | 43.95M |
| Net Income (ttm) | -43.5M |
| EPS (ttm) | -3.47 |
| PE Ratio (ttm) | -0.22 |
| Forward PE | -0.47 |
| Analyst | Hold |
| Ask | 0.85 |
| Volume | 6,701 |
| Avg. Volume (20D) | 49,983 |
| Open | 0.76 |
| Previous Close | 0.75 |
| Day's Range | 0.75 - 0.85 |
| 52-Week Range | 0.72 - 10.50 |
| Beta | 0.77 |
About HOOK
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-2...
Analyst Forecast
According to 3 analyst ratings, the average rating for HOOK stock is "Hold." The 12-month stock price forecast is $4.5, which is an increase of 478.41% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago · proactiveinvestors.co.uk
Gilead backs proposed Poolbeg Pharma's proposed tie-up with HOOKIPAGilead Sciences Inc (NASDAQ:GILD, ETR:GIS), the largest shareholder in HOOKIPA Pharma, has thrown its backing behind the proposed merger with Poolbeg Pharma PLC (AIM:POLB). Gilead, which holds just un...